Recruiting multiethnic populations to preclinical Alzheimers disease trials-Diversity Supplement

招募多种族人群参加临床前阿尔茨海默病试验-多样性补充

• 批准号: 10791432
• 负责人: Joshua Grill
• 金额: $ 9.34万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10791432
• 关键词: Affect; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Assessment tool; Attitude; Biological Markers; Clinical Trials; Communities; Data; Disclosure; Disease Progression; Enrollment; Ethics; Ethnic Origin; Ethnic Population; Face; Health system; Impaired cognition; Learning; Parents; Participant; Persons; Population Heterogeneity; Process; Public Health; Race; Research; Research Personnel; Research Project Grants; Role; Testing; Underrepresented Populations; Work; clinical trial enrollment; cognitive interview; ethnic difference; informant; multi-ethnic; pre-clinical; preclinical trial; racial difference; racial population; recruit; willingness; Affect; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Assessment tool; Attitude; Biological Markers; Clinical Trials; Communities; Data; Disclosure; Disease Progression; Enrollment; Ethics; Ethnic Origin; Ethnic Population; Face; Health system; Impaired cognition; Learning; Parents; Participant; Persons; Population Heterogeneity; Process; Public Health; Race; Research; Research Personnel; Research Project Grants; Role; Testing; Underrepresented Populations; Work; clinical trial enrollment; cognitive interview; ethnic difference; informant; multi-ethnic; pre-clinical; preclinical trial; racial difference; racial population; recruit; willingness

Abstract of Parent Research Project Alzheimer’s disease (AD) and related dementias (ADRD) disproportionately affect underrepresented racial and ethnic communities. The number of people with Alzheimer’s is expected to increase in the coming years, and with this an increased burden to the public health system. To alleviate this, it is important to find treatments through clinical trials that can slow disease progression, especially in diverse populations. Preclinical AD trials lack diversity, and the trial requirements of learning one’s biomarker status and needing a study partner to enroll could play a role. Our project focuses on understanding how the impact of these preclinical trial requirements, biomarker disclosure and study partner requirement, differs among racial and ethnic groups. We will use cognitive interviews to test our hypothesis that racial and ethnic groups differ in their willingness to learn biomarker status. We will also use a previously developed assessment instrument1, to assess attitudes toward the study partner requirement among diverse groups. We believe that the study partner requirement differentially affects ability/willingness to participate among racial and ethnic groups. This work will help us collect data to guide recruitment in preclinical AD trials in underrepresented groups, better understand attitudes toward biomarker disclosure during the research process and understand the differences in attitudes toward the study partner requirement so investigators can adjust to help underrepresented groups fill this role.

家长研究项目摘要 阿尔茨海默氏病（AD）和相关痴呆症（ADRD）不成比例地影响了代表性不足的种族和 族裔社区。预计未来几年患有阿尔茨海默氏症的人数将增加， 随着这增加了公共卫生系统的燃烧。为了减轻这一点，重要的是要找到治疗方法 通过可以减缓疾病进展的临床试验，尤其是在潜水员种群中。临床前广告试验 缺乏多样性，以及学习生物标志物身份并需要学习伙伴的试验要求 可以发挥作用。我们的项目专注于了解这些临床前试验要求的影响如何， 生物标志物披露和研究合作伙伴的要求，种族和族裔群体之间有所不同。我们将使用 认知访谈来检验我们的假设，即种族和种族的学习意愿有所不同 生物标志物状态。我们还将使用先前开发的评估工具1来评估与会者 潜水员群体之间的研究伙伴要求。我们认为学习伙伴的要求有所不同 影响在种族和族裔群体之间参与的能力/意愿。这项工作将帮助我们收集数据 指导代表性不足的临床前广告试验招聘，更好地了解与会者 生物标志物在研究过程中披露，并了解研究的出勤差异 合作伙伴的要求，因此调查人员可以调整以帮助代表性不足的小组填补这一角色。